Acadia Pharmaceuticals reported $96.68M in Selling and Administration Expenses for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Acadia Pharmaceuticals ACAD:US $ 96.68M 9.23M
Alnylam Pharmaceuticals ALNY:US $ 154.47M 31.91M
Aptinyx Inc APTX:US $ 5.78M 661K
Biogen BIIB:US $ 634.9M 153M
Biomarin Pharmaceutical BMRN:US $ 194.62M 22.94M
Bristol Myers Squibb BMY:US $ 1.83B 523M
Cara Therapeutics CARA:US $ 9.32M 2.16M
Corcept Therapeutics CORT:US $ 37.55M 5.26M
Cytokinetics CYTK:US $ 33.07M 736K
Eisai 4523:JP 110.49B 9.03B
Eli Lilly And LLY:US $ 1.56B 34.1M
Intercept Pharmaceuticals ICPT:US $ 50.01M 10.58M
Intra Cellular Therapies ITCI:US $ 75.46M 4.22M
Johnson & Johnson JNJ:US $ 5.94B 1.22B
Marinus Pharmaceuticals MRNS:US 11.74M 1.12M
Moderna Inc MRNA:US 268M 67M
Prothena PRTA:US 11.84M 371K
Ptc Therapeutics PTCT:US $ 73.27M 13.28M
Sarepta Therapeutics SRPT:US $ 71.84M 6.22M
Seattle Genetics SGEN:US $ 174.22M 36.71M
Ultragenyx Pharmaceutical RARE:US $ 67.31M 7.88M
Vanda Pharmaceuticals VNDA:US $ 40.85M 7.4M
Vertex Pharmaceuticals VRTX:US $ 215.2M 39.96M
YTE INCY:US $ 209.58M 16.62M